The agency first approved Sutent in 2006 to treat patients with gastrointestinal stromal tumors and advanced kidney cancer. The drug has also been approved to treat a certain form of pancreatic cancer.
Under the latest approval, Sutent may now be used to treat patients who’ve had a kidney surgically removed to lower the risk of cancer recurrence. Sutent is the first drug approved for this indication.
More articles on supply chain:
Geisinger, Intermountain among 11 healthcare groups urging CMS to add device identifiers to claims form
Genentech earns FDA approval for hemophilia drug
6 must-reads for supply chain leaders this week
